Ratings by Cantor Fitzgerald (Charles C. Duncan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/24/2025 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/16/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/22/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2025 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/19/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/13/2025 | GH Research PLC | GHRS | New Coverage | Overweight (N/A) |
14.00 (15.93) |
13.79% | Details | |
| 12/31/2024 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2024 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2024 | BioVie Inc. | BIVI | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2024 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2024 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/21/2023 | Seelos Therapeutics | SEEL | Downgrade | Neutral (Overweight) |
1.00 (1.28) |
28% | Details | |
| 9/11/2023 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2023 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2023 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/12/2023 | Oramed Pharma | ORMP | Downgrade | Neutral (Overweight) |
10.79 (3.29) |
-69.51% | Details | |
| 8/3/2022 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/22/2022 | BioVie Inc. | BIVI | New Coverage | Overweight (N/A) |
2.10 (1.36) |
-35.24% | Details | |
| 4/14/2022 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Overweight (N/A) |
50.85 (28.33) |
-44.29% | Details | |
| 3/23/2022 | Lucid Diagnostics Inc | LUCD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/18/2022 | Oramed Pharma | ORMP | New Coverage | Overweight (N/A) |
10.63 (3.29) |
-69.05% | Details | |
| 11/8/2021 | Lucid Diagnostics Inc | LUCD | New Coverage | Overweight (N/A) |
9.52 (1.40) |
-85.29% | Details | |
| 8/26/2021 | Cybin Inc. | CYBN | New Coverage | Overweight (N/A) |
2.28 (8.28) |
263.16% | Details | |
| 7/15/2021 | Cassava Sciences | SAVA | Maintain | Neutral (Overweight) |
|
Details | ||
| 6/1/2021 | Seelos Therapeutics | SEEL | New Coverage | Overweight (N/A) |
3.08 (1.28) |
-58.44% | Details | |
| 4/20/2021 | Ovid Therapeutics Inc | OVID | Downgrade | Neutral (Buy) |
3.78 (1.91) |
-49.47% | Details | |
| 2/10/2021 | Denali Therapeutics Inc. | DNLI | Upgrade | Overweight (Neutral) |
76.96 (19.69) |
-74.42% | Details | |
| 2/3/2021 | GW Pharma | GWPH | Downgrade | Neutral (Overweight) |
146.25 (218.96) |
49.72% | Details | |
| 12/23/2020 | Voyager Therapeutics | VYGR | Downgrade | Neutral (Overweight) |
9.03 (3.90) |
-56.81% | Details | |
| 12/2/2020 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 10/23/2020 | Cassava Sciences | SAVA | New Coverage | Overweight (N/A) |
8.91 (2.03) |
-77.22% | Details | |
| 5/11/2020 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/27/2020 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 12/30/2019 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 12/16/2019 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 12/3/2019 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2019 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2019 | Ovid Therapeutics Inc | OVID | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2019 | Crinetics | CRNX | New Coverage | Overweight (N/A) |
25.19 (38.23) |
51.77% | Details | |
| 1/29/2019 | Denali Therapeutics Inc. | DNLI | Downgrade | Neutral (Overweight) |
21.85 (19.69) |
-9.89% | Details | |
| 11/15/2018 | Ovid Therapeutics Inc | OVID | New Coverage | Overweight (N/A) |
5.16 (1.91) |
-62.98% | Details | |
| 11/15/2018 | Otonomy | OTIC | New Coverage | Overweight (N/A) |
2.41 (0.08) |
-96.68% | Details | |
| 11/15/2018 | Denali Therapeutics Inc. | DNLI | New Coverage | Overweight (N/A) |
17.27 (21.85) |
26.52% | Details | |
| 11/15/2018 | Axsome Therapeutics | AXSM | New Coverage | Overweight (N/A) |
2.90 (162.33) |
5497.59% | Details | |
| 11/15/2018 | Aptinyx | APTX | New Coverage | Overweight (N/A) |
25.51 (0.06) |
-99.76% | Details |
